NCT06602674Completed
PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions
PET/CT Imaging-Based Distinction of Pulmonary Lymphoma and Other Hypermetabolic Lesions Via Imaging Manifestations and Machine Learning Techniques: a Multicenter Retrospective Study
Source: ClinicalTrials.gov · Last updated 23 Jul 2025
Brief summary (registry, in English)
First, we analyse the types, imaging findings and relevant treatment responses based on PET/CT to complete a more comprehensive view of pulmonary lymphomas. Then, some models based on radiomics features will be developed to verify the possibility of differentiating pulmonary lymphomas via machine learning and develop a multi-class classification model. The final objective of this study is to develop a set of deep learning models for preliminary lung lesion segmentation and multi-class classification. The models will classify FDG-avid lung lesions into four groups, each defined by their pathological origin, primary therapy and relevant clinical department.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 647 (actual)
- First submitted
- 11 Sept 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 20 Jul 2024
- Lead sponsor
- Ruijin Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06602674
What you commit to
- Study type: Observational
- Participants enrolled: 647
- From 1 Apr 2024 to the primary completion date, 20 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Poor image quality;
- Inability to delineate the boundaries of lung lesions on CT images;
- Artifacts caused by nearby devices such as stents or drainage tubes.
Who the study is looking for
- Adult patients (≥18 years);
- Primary or recurrent lymphoma, ≥6 months from last treatment; primary lung cancer patients without prior malignancy;
- Benign solid lung lesions, without prior malignancy;
- Pulmonary metastasis, untreated with lung radiotherapy or particle implantation;
- Baseline assessment revealing PET-positive pulmonary lesions.
- Pathological results within 3 months of exam date, confirmed lung lesion types via tracheoscopy, lung puncture, or surgery.
- Baseline pulmonary lesions remaining considered to be pulmonary lymphoma (or metastases) based on follow-up clinical and imaging evaluation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.